cognitive impairment. Alzheimer’s Association. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. 2022. Accessed January 8, 2023.; https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf

4983

Sherzai D, Sherzai A. Preventing Alzheimer’s: our most urgent health care priority. Am J Lifestyle Med. 2019;13(5):451–61. https://pubmed.ncbi.nlm.nih.gov/31523210/

4984

de la Torre JC. A turning point for Alzheimer’s disease? Biofactors. 2012;38(2):78–83. https://pubmed.ncbi.nlm.nih.gov/22422426/

4985

Lopez OL, Kuller LH. Epidemiology of aging and associated cognitive disorders: prevalence and incidence of Alzheimer’s disease and other dementias. Handb Clin Neurol. 2019;167:139–48. https://pubmed.ncbi.nlm.nih.gov/31753130/

4986

Sengoku R. Aging and Alzheimer’s disease pathology. Neuropathol. 2020;40(1):22–9. https://pubmed.ncbi.nlm.nih.gov/31863504/

4987

Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM. Multiple pathologies are common and related to dementia in the oldest-old. Neurology. 2015;85(6):535–42. https://pubmed.ncbi.nlm.nih.gov/26180144/

4988

Viña J, Sanz-Ros J. Alzheimer’s disease: only prevention makes sense. Eur J Clin Invest. 2018;48(10):e13005. https://pubmed.ncbi.nlm.nih.gov/30028503/

4989

Román GC. Facts, myths, and controversies in vascular dementia. J Neurol Sci. 2004;226(1–2):49–52. https://pubmed.ncbi.nlm.nih.gov/15537519/

4990

Grau-olivares M, Arboix A. Mild cognitive impairment in stroke patients with ischemic cerebral small-vessel disease: a forerunner of vascular dementia? Expert Rev Neurother. 2009;9(8):1201–17. https://pubmed.ncbi.nlm.nih.gov/19673608/

4991

Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197–204. https://pubmed.ncbi.nlm.nih.gov/17568013/

4992

Murphy SL, Kochanek KD, Xu J, Arias E. Mortality in the United States, 2020. NCHS Data Brief. 2021;(427):1–8. https://pubmed.ncbi.nlm.nih.gov/34978528/

4993

Heron M. Deaths: leading causes for 2019. Natl Vital Stat Rep. 2021;70(9):1–114. https://pubmed.ncbi.nlm.nih.gov/34520342/

4994

Haaksma ML, Eriksdotter M, Rizzuto D, et al. Survival time tool to guide care planning in people with dementia. Neurology. 2020;94(5):e538–48. https://pubmed.ncbi.nlm.nih.gov/31843808/

4995

Lopez OL, Kuller LH. Epidemiology of aging and associated cognitive disorders: prevalence and incidence of Alzheimer’s disease and other dementias. Handb Clin Neurol. 2019;167:139–48. https://pubmed.ncbi.nlm.nih.gov/31753130/

4996

Cahill S, Pierce M, Werner P, Darley A, Bobersky A. A systematic review of the public’s knowledge and understanding of Alzheimer’s disease and dementia. Alzheimer Dis Assoc Disord. 2015;29(3):255–75. https://pubmed.ncbi.nlm.nih.gov/26207322/

4997

Goodwin JS. Geriatric ideology: the myth of the myth of senility. J Am Geriatr Soc. 1991;39(6):627–31. https://pubmed.ncbi.nlm.nih.gov/2037757/

4998

Takao M, Hirose N, Arai Y, Mihara B, Mimura M. Neuropathology of supercentenarians – four autopsy case studies. Acta Neuropathol Commun. 2016;4(1):97. https://pubmed.ncbi.nlm.nih.gov/27590044/

4999

den Dunnen WFA, Brouwer WH, Bijlard E, et al. No disease in the brain of a 115-year-old woman. Neurobiol Aging. 2008;29(8):1127–32. https://pubmed.ncbi.nlm.nih.gov/18534718/

5000

Williams RW, Herrup K. The control of neuron number. Annu Rev Neurosci. 1988;11:423–53. https://pubmed.ncbi.nlm.nih.gov/3284447/

5001

von Bartheld CS. Myths and truths about the cellular composition of the human brain: a review of influential concepts. J Chem Neuroanat. 2018;93:2–15. https://pubmed.ncbi.nlm.nih.gov/28873338/

5002

Sherzai D, Sherzai A. Preventing Alzheimer’s: our most urgent health care priority. Am J Lifestyle Med. 2019;13(5):451–61. https://pubmed.ncbi.nlm.nih.gov/31523210/

5003

Cahill S, Pierce M, Werner P, Darley A, Bobersky A. A systematic review of the public’s knowledge and understanding of Alzheimer’s disease and dementia. Alzheimer Dis Assoc Disord. 2015;29(3):255–75. https://pubmed.ncbi.nlm.nih.gov/26207322/

5004

Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;2018(6):CD001190. https://pubmed.ncbi.nlm.nih.gov/29923184/

5005

McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3:CD003154. https://pubmed.ncbi.nlm.nih.gov/30891742/

5006

Schmitt HP. On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease. Med Hypotheses. 2005;65(2):259–65. https://pubmed.ncbi.nlm.nih.gov/15922097/

5007

Blanco-Silvente L, Castells X, Garre-Olmo J, et al. Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer’s disease: a cumulative meta-analysis and trial sequential analysis. Eur J Clin Pharmacol. 2019;75(12):1659–67. https://pubmed.ncbi.nlm.nih.gov/31435707/

5008

Fink HA, Linskens EJ, MacDonald R, et al. Benefits and harms of prescription drugs and supplements for treatment of clinical Alzheimer-type dementia. Ann Intern Med. 2020;172(10):656–68. https://pubmed.ncbi.nlm.nih.gov/32340037/

5009

Blanco-Silvente L, Castells X, Garre-Olmo J, et al. Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer’s disease: a cumulative meta-analysis and trial sequential analysis. Eur J Clin Pharmacol. 2019;75(12):1659–67. https://pubmed.ncbi.nlm.nih.gov/31435707/

5010

Rabinovici GD. Controversy and progress in Alzheimer’s disease – FDA approval of aducanumab. N Engl J Med. 2021;385(9):771–4. https://pubmed.ncbi.nlm.nih.gov/34320284/

5011

Robinson JC. Why is aducanumab priced at $56,000 per patient? Lessons for drug-pricing reform. N Engl J Med. 2021;385(22):2017–9. https://pubmed.ncbi.nlm.nih.gov/34797614/

5012

Moghavem N, Henderson VW, Greicius MD. Medicare should not cover aducanumab as a treatment for Alzheimer’s disease. Ann Neurol. 2021;90(3):331–3. https://pubmed.ncbi.nlm.nih.gov/34278596/

5013

Rubin R. Recently approved Alzheimer drug raises questions that might never be answered. JAMA. 2021;326(6):469–72. https://pubmed.ncbi.nlm.nih.gov/34287610/

5014

Crosson FJ, Covinsky K, Redberg RF. Medicare and the shocking US Food and Drug Administration approval of aducanumab: crisis or opportunity? JAMA Intern Med. 2021;181(10):1278–80. https://pubmed.ncbi.nlm.nih.gov/34254992/

5015

Crosson FJ, Covinsky K, Redberg RF. Medicare and the shocking US Food and Drug Administration approval of aducanumab: crisis or opportunity? JAMA Intern Med. 2021;181(10):1278–80. https://pubmed.ncbi.nlm.nih.gov/34254992/

5016

Rubin R. Recently approved Alzheimer drug raises questions that might never be answered. JAMA. 2021;326(6):469–72. https://pubmed.ncbi.nlm.nih.gov/34287610/

5017

Lundebjerg NE. My head just exploded, now what? Aducanumab. J Am Geriatr Soc. 2021;69(9):2689–91.